key: cord-0727222-6jk75itk
authors: Blanco, J.R.; Cobos-Ceballos, M.J.; Navarro, F.; Sanjoaquin, I.; Arnaiz de las Revillas, F.; Bernal, E.; Buzon-Martin, L.; Viribay, M.; Romero, L.; Espejo-Pérez, S.; Valencia, B.; Ibañez, D.; Ferrer-Pargada, D.; Malia, D.; Gutierrez-Herrero, F.G.; Olalla, J.; Jurado-Gamez, B.; Ugedo, J.
title: Pulmonary long-term consequences of COVID-19 infections after hospital discharge
date: 2021-03-02
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.02.019
sha: c31e0fb1eb99a2624671a827865e2900129035de
doc_id: 727222
cord_uid: 6jk75itk

OBJECTIVES: COVID-19 survivors are reporting residual abnormalities after discharge from the hospital. Limited information is available about this stage of recovery or the lingering effects of the virus on pulmonary function and inflammation. The aim of this study was to describe lung function and to identify biomarkers in serum and induced sputum samples from patients recovering from COVID-19 hospitalisation. METHODS: Patients admitted to Spanish hospitals with laboratory-confirmed COVID-19 infection by a real-time PCR (RT-PCR) assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were recruited for this study. Each hospital screened their lists of discharged patients at least 45 days after symptom onset. SARS-CoV-2-infected patients were divided into mild/moderate and severe disease groups according to the severity of their symptoms during hospitalisation. Patients’ epidemiological and medical histories, comorbidities, chronic treatments, and laboratory parameters were evaluated. Pulmonary function tests, the standardised 6-minute walk test (6 MWT) and chest computed tomography (CT) were also performed. The levels of proteases, their inhibitors, and shed receptors were measured in serum and induced sputum samples. RESULTS: A total of 100 patients with respiratory function tests were included in this study. The median number of days after the onset of symptoms was 104 (IQR 89.25, 126.75). COVID-19 was severe in 47% (47/100) of patients. CT was normal in 48% (48/100) of patients. Lung function was normal (FEV1 ≥80%, FVC ≥80%, FEV1/FVC ≥0.7, and diffusing capacity for carbon monoxide [DLCO] ≥80%) in 92% (92/100), 94% (94/100), 100% (100/100) and 48% (48/100) of patients, respectively. Multivariate analysis showed that a DLCO <80% (OR 5.92; 95%CI 2.28-15.37; p <0.0001) and a lower serum LDH level (OR 0.98; 95%CI 0.97-0.99) were associated with the severe disease group of SARS-CoV-2 during hospital stay. CONCLUSIONS: A diffusion deficit (DLCO <80%) was still present after hospital discharge and was associated with the most severe SARS-CoV-2 cases.

Approximately 104 million individuals worldwide have recovered from COVID-19 (https://coronavirus.jhu.edu/map.html). However, some survivors report persistent severe symptoms and organ dysfunction [1] . These symptoms might be, in part, a consequence of the cytokine storm suffered in the acute phase of the infection [2] . Previous studies have shown that higher levels of proinflammatory cytokine responses during the acute phase of other coronavirus infections such as severe acute respiratory syndrome (SARS) [3] and the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) [4] , were associated with severe lung disease. Unlike previous coronaviruses, COVID -19 does not seem to be just a respiratory affliction; rather, it is a viral infectious process involving multiple systems [5] .

Residual lung abnormalities have been found in patients with SARS-CoV-2 1-3 months after discharge from the hospital [6] [7] [8] [9] . However, limited information is available about the serum inflammatory state during recovery from SARS-CoV-2. The impact of residual inflammation on the lungs is even rarer. Because the persistence of this inflammatory state in blood and sputum could have important prognostic implications, we performed this study.

This was a prospective study of patients older than 18 years of age who were admitted to different Spanish hospitals with laboratory-confirmed COVID-19 infection by real-time PCR (RT-PCR) assay for SARS-CoV-2. Each hospital screened their lists of discharged patients. These patients were interviewed by phone at least 45 days after symptom onset and asked to collaborate if they met inclusion criteria. Exclusion criteria included patients with a need for prior invasive mechanical ventilation, chronic infectious diseases, chronic lung diseases, concurrent autoimmune or cancer diseases, chronic use of corticosteroids or immunosuppressive therapy, pregnancy, alcohol/drug abuse, or patients whose conditions did not allow participation in this study. The study was approved by the Institutional Research Ethics Committees. All participants provided written informed consent.

Patients were divided into mild (mild and moderate) and severe groups according to the severity of their symptoms during their hospital stays. The mild group did not have pneumonia imaging; the moderate group showed pneumonia; and the severe group had dyspnoea, respiratory frequency ≥ 30/minute, blood oxygen saturation ≤93%, PaO 2 /FiO 2 ratio <300, and/or lung infiltrates >50% of the lung field within 24-48 hours [10] . Patients requiring invasive mechanical ventilation were excluded because of its impact on systemic inflammation [11] .

Epidemiological, medical history, comorbidities, chronic treatments, and laboratory parameters were evaluated. Smoking status was determined from self-administered survey responses. Anthropometric measurements included body mass index (BMI). At least 45 days after symptom onset, pulmonary function testing, standardised 6-minute walk tests (6 MWT) [12] , and chest computed tomography (CT) were performed. Lung function included forced vital capacity (FVC), forced expiratory volume in the first second (FEV1), FEV1/FVC ratio and diffusion capacity of the lung for carbon monoxide (DLCO). Diffusion deficit was considered a DLCO <80% of the predicted value [13] . The 6 MWT, a practical and simple test that provides a global measure of functional capacity, was performed in accordance with international recommendations [12] .

Peripheral oxygen saturation (SpO 2 ) was monitored using a handheld oximeter. ∆SpO 2 -6 MWT was defined as the difference between the resting and nadir SpO 2 . The 6 MWT distance was also evaluated [14] . CT was considered normal in the absence of ground-glass opacification, crazy-paving patterns, consolidation, or linear opacities [15] .

The levels of biomarkers were measured in serum and induced sputum samples. Serum samples were obtained from blood drawn at a date close to the tests already described and stored at -80ºC. Sputum was induced as previously described [16] and stored at -80°C. It was obtained, whenever possible, on the Table 1 ). All samples were tested individually (one sample per well), but samples from all groups were measured on the same plate. The hook effect, a state of antigen excess relative to the antibody probes, resulting in falsely lowered values, was ruled out after analysing undiluted and diluted samples.

Categorical variables were reported as frequencies and proportions. Continuous Fisher's exact test was used for each categorical variable, as appropriate. For quantitative variables, the nonparametric Mann-Whitney U test was used.

Multivariate analysis was carried out using binary logistic regression with the forward conditional method, introducing DLCO (<80 vs. ≥80%) as the dependent variable. Independent variables were all variables that were statistically significant in the bivariate analysis, or clinical implications. The results of the multivariate model were adjusted, and we present the odds ratio and its 95% confidence interval (CI). Statistical significance was set at p <0.05.

Analyses were performed using SPSS 24.0 software (SPSS Inc., Chicago, IL, USA).

A total of 108 patients were included in this study. Given the high percentage of subjects with DLCO <80% and its involvement in lung damage, this lung parameter was evaluated. Table 1 shows the patient characteristics according to DLCO severity. With the exception of significant data referring to the severity of COVID-19 disease during hospitalisation and the length of hospital, no other significant differences were observed. Table 2 shows the analytical parameters according to DLCO severity. Finally, Table 3 provides information about the tests carried out and the minimum time elapsed until tests were performed. No differences were observed after analysing ∆SpO 2 -6 MWT (data not shown).

Multivariate analysis showed that a DLCO <80% was associated with severe disease in the SARS-CoV-2 group during their hospital stays (OR 5.92; 95% CI 2.28-15.37; p <0.0001) as were lower serum LDH levels (OR 0.98; 95% CI 0.97-0.99; p 0.002).

Since the SARS-CoV-2 outbreak, there has been increasing concern about the potential risk of parenchymal fibrosis and lung function impairment. The most important factor is lung diffusion capacity [17] . Zhao et al. [6] reported that three months after COVID-19 discharge, a high percentage of CT abnormalities (70.9%) and DLCO anomalies (16.4%) were still present in recovering patients.

Other authors, such as Mo et al. [7] , reported that nearly a month after hospital discharge that, regardless of the degree of SARS-CoV-2 severity, no significant differences in FEV1, FVC, or its ratio were observed. However, the DLCO value was significantly lower as the severity of the clinical picture increased (47.2% in total; 30.4% in mild illness and 84.2% in severe pneumoniae). In this study, the authors included a small number of patients with previous pulmonary pathology, J o u r n a l P r e -p r o o f one of the exclusion criteria of our study. Likewise, Frija-Masson et al. [9] also observed that more than half of patients with COVID-19 pneumonia, some of whom had respiratory comorbidities, exhibited abnormal lung function one month after symptom onset, without a clear relationship with pneumonia extent on chest CT. Huang et al. [18] observed that 30 days after discharge from the hospital, patients exhibited nearly significant differences in DLCO values (<80%), 42.5% in non-severe cases, and 75.6% in severe cases (p < 0.053). In that study, patients with a previous history of pulmonary resection, neurological disease, or mental illness were excluded. In our study, DLCO findings were close to those observed by Mo et al. [7] and Huang et al. [18] , while the CT findings were clearly better than those reported by Zhao et al. [6] .

After the 2003 outbreak of SARS, survivors evaluated within three months of discharge showed that lung fibrotic changes occurred mostly in severely sick patients [19] . These same authors also observed that when assessing lung fibrotic changes, DLCO scores were more sensitive than chest radiography and/or high-resolution CT. These results are similar to those observed by our group. During the follow-up of SARS patients, abnormal CT (30%) and impaired DLCO function (15.5%) [20] were still present six months later. These authors also observed significant impairment in DLCO function (23.7%) one year after illness onset [21] . All these data suggest that some of the recovered COVID-19 patients will have significantly impaired lung function months after discharge.

Contrary to our expectations, LDH levels were significantly lower in patients with DLCO abnormalities (<80%). However, serum LDH is a sensitive, burdensome marker for cell injury [22] . One of the reasons could be that its levels vary in multiple circumstances (cell damage related to ischaemia, exposure to bacterial toxins, chemical poisoning, etc.), which is why serum LDH is difficult to use as a valid biomarker of lung damage or inflammation [22] . However, some authors have observed that LDH (cut-off value of 344.5 U/L) could be a predictive factor for early recognition of lung injury and severe COVID-19 cases [23] . These levels are clearly higher than those presented by our patients.

Although the 6 MWT is a validated clinical test designed for use in adults with chronic respiratory disease [24, 25] , it could be an appropriate test to triage COVID-19 patients. In fact, Huang et al. [18] observed that severe SARS-CoV-2 patients had a greater 6 MWT decline than non-severe patients. In our study, although the distances covered were significantly lower in patients with abnormal DLCO values, these differences disappeared after multivariate analysis.

Sputum induction is a noninvasive method that has been employed to evaluate bronchial inflammation in patients with asthma and other respiratory diseases [26] . This technique allows us to obtain small sputum macrophages that exhibit features of highly active inflammatory cells that could be used to evaluate inflammatory biomarkers [27] . In our study, we considered it necessary to measure both markers in serum and in induced sputum because it was unlikely that analysis of serum markers alone would be enough to reflect an ongoing residual pulmonary inflammatory state. For example, Ropcke et al. [28] observed few and weak correlations between lung and serum markers in chronic obstructive pulmonary disease patients. Contrary to our expectations, we observed that none of the parameters analysed correlated with the alterations observed in pulmonary diffusion.

Multiple mechanisms of lung injury in COVID-19 patients have been described [29] . However, the mechanisms underlying the potential long-term pathogenicity of SARS-CoV-2 have not been studied thus far. For this reason, multiple biomarkers implicated in pulmonary fibrosis were evaluated [30, 31] . To the best of our knowledge, they have not been evaluated in COVID-19 patients.

Although PAI levels are significantly elevated in the plasma of hospitalised COVID-19 patients [32] and mRNA levels are higher in the lungs of COVID-19 patients than in those of uninfected or influenza patients [33] , we did not find differences, perhaps because we analysed a non-acute phase. Finally, ICAM, which is also elevated in the sera of patients with pulmonary fibrosis [34] , in the context of the first transcriptomic analysis performed to date on SARS-CoV-2 and IPF, showed that it has a relevant role in both processes [35] . In our study, J o u r n a l P r e -p r o o f we found no significant differences. Thus, we need to continue studying biomarkers that might identify the potential progression of lung damage.

Our study has some limitations. First, this study included a small number of patients, so results should be interpreted with caution. Statistical nonsignificance may not rule out differences between severe and mild/moderate cases. In the same way, there was no comparison group (control group).

However, that was not the aim of the study because it was focused on SARS-CoV-2 survivors. Second, at the time we planned this study, there was a deep concern about the potential sequelae of this infection and whether any early intervention was required. Third, although it has been suggested that the viral load of SARS-CoV-2 could be a useful marker for assessing disease severity and prognosis [36] , we did not include it by assuming that this was related to the severity of the clinical picture. Fourth, although the use of corticosteroids or other immunosuppressive agents was not evaluated, their use could be supposed based on the severity of the disease. This study was carried out before these agents were considered a therapeutic option for COVID-19

patients. Finally, this study has other strengths such as the decision to include the non-invasive induced sputum procedure.

In summary, this study has shown that a high proportion of severely affected COVID-19 patients show impairment in DLCO measurements in the first few months after symptoms onset. Although its long-term impact is still unknown, DLCO could be considered a useful tool to identify individuals at risk for pulmonary sequelae. It will be necessary to follow these patients for longer Financial support. This work was supported by the "Convocatoria de expresiones de interés para la financiación de proyectos de investigación sobre el SARS-CoV-2 y la enfermedad COVID" from Instituto de Salud Carlos III (Project COV20/00401).

J o u r n a l P r e -p r o o f 

Long-term health consequences of COVID

COVID-19: consider cytokine storm syndromes and immunosuppression

Analysis of serum cytokines in patients with severe acute respiratory syndrome

MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery

Abnormal pulmonary function in COVID-19 patients at time of hospital discharge

Analysis of thin-section CT in patients with coronavirus disease (COVID-19) after hospital discharge

Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection

Report of the WHO-China Joint Mission on Coronavirus Disease

Mechanical ventilation drives inflammation in severe viral bronchiolitis

ATS statement: guidelines for the six-minute walk test

Interpretative strategies for lung function tests

Distance covered during a six-minute walk test predicts long-term cardiovascular mortality and hospitalisation rates in men with systolic heart failure: an observational study

Chest CT findings of COVID-19 pneumonia by duration of symptoms

Standardised methodology of sputum induction and processing

Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis

Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase

Follow-up study on pulmonary function and lung radiographic changes in rehabilitating severe acute respiratory syndrome patients after discharge

Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors

The 1-year impact of severe acute respiratory syndrome on pulmonary function, exercise capacity, and quality of life in a cohort of survivors

Clinical use of biomarkers of survival in pulmonary fibrosis

Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study

measurement properties of field walking tests in chronic respiratory disease

technical standard: field walking tests in chronic respiratory disease

Sputum biomarker profiles in cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) and association between pulmonary function

Characterization of a population of small macrophages in induced sputum of patients with chronic obstructive pulmonary disease and healthy volunteers

Repeatability of and relationship between potential COPD biomarkers in bronchoalveolar lavage, bronchial biopsies, serum, and induced sputum

Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV

Osteoprotegerin is elevated in pulmonary fibrosis and associates with IPF progression

Approaching the degradome in idiopathic pulmonary fibrosis

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a singlecentre, cross-sectional study

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

ICAM-1, ICAM-2 and ICAM-3 in the sera of patients with idiopathic pulmonary fibrosis

Network-based identification genetic effect of SARS-CoV-2 infections to Idiopathic pulmonary fibrosis (IPF) patients. Brief Bioinform

Viral dynamics in mild and severe cases of COVID-19

FEV1 >80%, n (%)

6MWT distance, mean (± SD) 6MWT distance >550,n (%)